News

Collaboration combines Novo Nordisk’ s scientific leadership in obesity and cardiometabolic diseases with Septerna’ s expertise in G protein-coupled receptor drug discovery Goal is to develop ...
Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills. Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ...
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral ...
Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market.
Summary. Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.
The Novo Nordisk partnership comes as a pleasant surprise for Septerna investors, as the stock has languished since the company went public in Oct. 25, 2024 at an initial public offering price of $18.
Novo Nordisk said on Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to competitor Eli Lilly’s efforts to bring a more ...